Join
Live feed
·
INSIDERFilingvia Quantisnow
Acrivon Therapeutics Inc. logo

Chief Development Officer Gamelin Erick sold $804 worth of shares (400 units at $2.01), decreasing direct ownership by 0.75% to 52,592 units (SEC Form 4) (for tax liability)

ByQuantisnow·Wall Street's wire, on your screen.
ACRV· Acrivon Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ACRV (Acrivon Therapeutics Inc.) and more on Quantisnow.